Aurobindo Pharma

Reasons for buying:

Buy PE was reasonable at 15.82 and below 10 years PE median of 16.57.

Earnings have blown up in the last decade.

Return on equity is excellent at 27.54%.

The debt of the company is ₹5,561.97cr with ₹2,842.17cr in cash.

The market cap of the company is ₹57,079.21cr.

Buy date: 29-Sep-2020

Qty: 12   Buy Price: ₹803.54   Buy EPS: 50.79   Buy PE: 15.82

Q4 results were released on 31st May and the current EPS is 91.05 up about 79.27% from my buy EPS.

The price of the stock is up about 21.54% from my buy price and hoping for a multi-bagger in a few years.

Price dropped by 10% so added 10k worth.

Buy date: 18-Aug-2021

Qty: 13   Buy Price: ₹723.00   Buy EPS: 90.87   Buy PE: 7.95

Price dropped by 10% so added 10k worth.

Buy date: 18-Nov-2021

Qty: 15   Buy Price: ₹640.85   Buy EPS: 89   Buy PE: 7.2

I will stop buying when EPS falls to 40.17.

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.